Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01RUK
|
|||
| Drug Name |
PMID25666693-Compound-104
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Cancer related pain [ICD-11: MG30; ICD-10: R52.1, R52.2] | Patented | [1] | |
| Inflammatory pain [ICD-11: MG30.42; ICD-10: R52, G89] | Patented | [1] | ||
| Neuropathic pain [ICD-11: 8E43.0] | Patented | [1] | ||
| Osteoarthritis pain [ICD-11: MG30.31] | Patented | [1] | ||
| Company |
Purdue Pharma L.P
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H20ClF4N3O3
|
|||
| Canonical SMILES |
C1CN(CCC1(C2=C(C=C(C=N2)C(CO)O)Cl)F)C(=O)NC3=CC=C(C=C3)C(F)(F)F
|
|||
| InChI |
1S/C20H20ClF4N3O3/c21-15-9-12(16(30)11-29)10-26-17(15)19(22)5-7-28(8-6-19)18(31)27-14-3-1-13(2-4-14)20(23,24)25/h1-4,9-10,16,29-30H,5-8,11H2,(H,27,31)/t16-/m1/s1
|
|||
| InChIKey |
DSVBUDHKIZVCPH-MRXNPFEDSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Transient receptor potential cation channel V1 (TRPV1) | Target Info | Antagonist | [1] |
| Target's Patent Info | Transient receptor potential cation channel V1 (TRPV1) | Target's Patent Info | [1] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Inflammatory mediator regulation of TRP channels | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Pathway Interaction Database | Trk receptor signaling mediated by the MAPK pathway | |||
| Trk receptor signaling mediated by PI3K and PLC-gamma | ||||
| Reactome | TRP channels | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.